These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7062411)

  • 1. Prognostic factors influencing survival of patients receiving intravesical epodyl.
    Riddle PR; Khan O; Fitzpatrick JM; Oliver RT
    J Urol; 1982 Mar; 127(3):430-2. PubMed ID: 7062411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up in patients with superficial bladder tumours treated with intravesical Epodyl.
    Fitzpatrick JM; Khan O; Oliver RT; Riddle PR
    Br J Urol; 1979 Dec; 51(6):545-8. PubMed ID: 534839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer].
    Flamm J; Kühnel W; Dona S
    Urologe A; 1989 Mar; 28(2):99-102. PubMed ID: 2655259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical ethoglucid (Epodyl) for treatment of noninvasive bladder cancer (stage Ta).
    Larson A; Fritjofsson A
    Ups J Med Sci; 1985; 90(2):127-32. PubMed ID: 3909592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of intravesical Epodyl therapy for superficial bladder cancer.
    Mufti GR; Virdi JS; Hall MH
    Br J Urol; 1990 Jan; 65(1):32-5. PubMed ID: 2310930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical epodyl in the management of bladder tumors: combined experience of the Yorkshire Urological Cancer Research Group.
    Robinson MR; Shetty MB; Richards B; Bastable J; Glashan RW; Smith PH
    J Urol; 1977 Dec; 118(6):972-3. PubMed ID: 926278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of Epodyl in aluminium foil cups as a cause of ineffective treatment of non-invasive bladder tumours.
    Larsen J
    Scand J Urol Nephrol; 1980; 14(3):239-42. PubMed ID: 7209431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical therapy.
    Herr HW
    Hematol Oncol Clin North Am; 1992 Feb; 6(1):117-27. PubMed ID: 1556045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium.
    Manyak MJ; Ogan K
    J Endourol; 2003 Oct; 17(8):633-9. PubMed ID: 14622483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracavitary Epodyl for multiple non-invasive, highly differentiated bladder tumours.
    Colleen S; Ek A; Hellsten S; Lindholm CE
    Scand J Urol Nephrol; 1980; 14(1):43-5. PubMed ID: 7375840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epodyl treatment of bladder tumours.
    Nielsen HV; Thybo E
    Scand J Urol Nephrol; 1979; 13(1):59-63. PubMed ID: 419386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epodyl treatment of bladder neoplasms].
    Hannestad R; Otnes B
    Tidsskr Nor Laegeforen; 1976 Jan; 96(1):25-7. PubMed ID: 1257948
    [No Abstract]   [Full Text] [Related]  

  • 13. Bladder cancer chemotherapy studies supported by the National Bladder Cancer Project.
    Friedell GH
    Cancer Chemother Pharmacol; 1983; 11 Suppl():S13-5. PubMed ID: 6416697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical chemotherapy of superficial bladder cancer.
    Lum BL
    Recent Results Cancer Res; 1983; 85():3-36. PubMed ID: 6408716
    [No Abstract]   [Full Text] [Related]  

  • 15. 5-year experience with intravesical therapy of carcinoma in situ: an inquiry into the risks of "conservative" management.
    Stanisic TH; Donovan JM; Lebouton J; Graham AR
    J Urol; 1987 Nov; 138(5):1158-61. PubMed ID: 3118055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma.
    Garnick MB; Schade D; Israel M; Maxwell B; Richie JP
    J Urol; 1984 Jan; 131(1):43-6. PubMed ID: 6690745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
    Steinberg G; Bahnson R; Brosman S; Middleton R; Wajsman Z; Wehle M
    J Urol; 2000 Mar; 163(3):761-7. PubMed ID: 10687972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ.
    Gaya JM; Palou J; Algaba F; Arce J; Rodríguez-Faba O; Villavicencio H
    Can J Urol; 2010 Oct; 17(5):5370-6. PubMed ID: 20974029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.